HER2-positive Breast Cancer
5 competing products in clinical development for HER2-positive Breast Cancer.
Pipeline by Phase
Pre-clinical2
Phase 11
Phase 22
All Products (5)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | Recruiting | 42 |
| Trastuzumab deruxtecan | Daiichi Sankyo | Pre-clinical | Recruiting | 33 |
| ALT-P7 (HM2-MMAE) | Alteogen | Phase 1 | Completed | 29 |
| Pertuzumab + Trastuzumab + eribulin | Eisai | Phase 2 | Terminated | 27 |
| Trastuzumab deruxtecan | Daiichi Sankyo | Pre-clinical | Completed | 26 |